ESMO interim update on first-line therapy in advanced urothelial carcinoma

European Society for Medical Oncology (ESMO) clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma

This ESMO Clinical Practice Guideline eUpdate addresses developments in first-line therapy in advanced urothelial carcinoma.

EV+P is the new standard of care in first-line advanced urothelial carcinoma.

Nivolumab–cisplatin–gemcitabine or platinum-based ChT and maintenance avelumab are alternatives if EV+P is not possible.


Read full Guideline